Wockhardt Limited Stock Price Today (NSE: WOCKPHARMA)
Fundamental Score
Wockhardt Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Wockhardt Limited share price today is ₹2021.50, down 2.06% on NSE/BSE as of 16 September 2026. Wockhardt Limited (WOCKPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹32.75K (Cr). The 52-week high for WOCKPHARMA share price is ₹2422.30 and the 52-week low is ₹1086.70. At a P/E ratio of 80.22x, WOCKPHARMA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 4.58% and a debt-to-equity ratio of 0.43.
Wockhardt Limited Share Price Chart — NSE/BSE Historical Performance
Wockhardt Limited share price chart: 15.16% return over the past month. 52-week high ₹2422.30, 52-week low ₹1086.70.
Wockhardt Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2050.00 | ₹2075.00 | ₹1967.30 | ₹2021.50 | 12.63L (Cr) | |
| ₹2190.00 | ₹2193.80 | ₹2055.00 | ₹2064.10 | 8.52L (Cr) | |
| ₹2200.00 | ₹2237.00 | ₹2167.30 | ₹2179.40 | 11.10L (Cr) | |
| ₹2250.00 | ₹2267.00 | ₹2197.00 | ₹2220.60 | 6.94L (Cr) | |
| ₹2225.00 | ₹2272.90 | ₹2196.00 | ₹2248.80 | 13.95L (Cr) | |
| ₹2200.00 | ₹2240.00 | ₹2166.00 | ₹2224.00 | 13.44L (Cr) | |
| ₹2112.50 | ₹2236.00 | ₹2076.20 | ₹2208.00 | 43.20L (Cr) | |
| ₹1980.00 | ₹2108.50 | ₹1976.10 | ₹2088.70 | 35.58L (Cr) | |
| ₹1904.60 | ₹1982.00 | ₹1891.40 | ₹1950.60 | 10.56L (Cr) | |
| ₹1846.20 | ₹1911.00 | ₹1838.00 | ₹1904.30 | 6.85L (Cr) |
Wockhardt Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1883.70 | ₹2272.90 | ₹1833.30 | ₹2021.50 | +7.32% | |
| ₹1967.00 | ₹2067.70 | ₹1814.40 | ₹1883.70 | -4.23% | |
| ₹1955.00 | ₹1994.00 | ₹1792.40 | ₹1959.70 | +0.24% | |
| ₹2377.00 | ₹2422.30 | ₹1820.00 | ₹1941.40 | -18.33% | |
| ₹1395.60 | ₹2097.40 | ₹1395.60 | ₹2031.40 | +45.56% | |
| ₹1234.00 | ₹1532.00 | ₹1198.40 | ₹1395.60 | +13.10% | |
| ₹1310.00 | ₹1347.40 | ₹1086.70 | ₹1175.70 | -10.25% | |
| ₹1348.60 | ₹1463.00 | ₹1275.00 | ₹1361.90 | +0.99% | |
| ₹1438.00 | ₹1529.00 | ₹1335.00 | ₹1382.20 | -3.88% | |
| ₹1245.10 | ₹1566.90 | ₹1225.20 | ₹1446.20 | +16.15% | |
| ₹1290.40 | ₹1433.00 | ₹1230.00 | ₹1235.00 | -4.29% | |
| ₹1510.00 | ₹1524.00 | ₹1276.00 | ₹1281.50 | -15.13% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Wockhardt Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Wockhardt Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WOCKPHARMA across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Strong Revenue Growth (25.88%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Risk Factors
10 factors identified
Below-Average Return on Equity (4.58%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.89%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 80.22x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (7.55x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-217.78%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (4.49% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-26.69% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-20.86% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.12x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Wockhardt Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Wockhardt Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Wockhardt LimitedWockhardt Limit...Selected✓ WOCKPHARMA • 532300 | 24.6/100 | ₹2021.50₹2022 | ₹32748.30₹32748.30 | 80.22Average 80.2 Average | 4.58%Poor 4.58% Poor | 6.89%Poor 6.89% Poor | 0.43Excellent 0.4 Excellent | -20.86%Poor -20.86% Poor | 4.49%Average 4.49% Average | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Wockhardt Limited Dividend History
Annual cash dividends paid by WOCKPHARMA — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹2.00 Cr |
| FY 2021 | ₹1.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Wockhardt Limited Quarterly Performance
Latest quarterly metrics for WOCKPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
25.88%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-217.78%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
4.49%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-20.86%
Compounded annual net profit growth over 5 years
Wockhardt Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for WOCKPHARMA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Wockhardt Limited Financial Statements
Annual income statement, balance sheet and cash flow for Wockhardt Limited (WOCKPHARMA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Wockhardt Limited
About WOCKPHARMA (Wockhardt Limited)
Wockhardt Ltd is a global pharmaceutical force, weaving a legacy of scientific advancement and healthcare solutions across diverse geographies. From its roots in India, the company... has cultivated a robust presence in the United States, Europe, and beyond, establishing itself as a key player in the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Wockhardt's commitment to innovation is evident in its pursuit of cutting-edge therapies and its unwavering dedication to improving patient outcomes worldwide. The company's expansive infrastructure and skilled workforce enable it to navigate the complexities of the global pharmaceutical landscape, ensuring the delivery of high-quality medicines to those in need. The company is deeply involved in crafting critical medicines that are delivered to the world's markets. In this arena, the organization is not just invested in established treatments. They are also committed to research and development of next generation solutions. It's research aims to address some of the most pressing health challenges. Wockhardt's R&D is designed to create solutions and treatments that improve health outcomes for people. This includes investment in advanced biotechnologies and novel drug delivery systems, showing a goal for progressive therapies and products. Wockhardt's product portfolio encompasses a wide array of therapeutic areas, and it has established a firm footprint in manufacturing and marketing complex generic formulations. The company maintains unwavering adherence to global regulatory standards and ethical practices, reflecting its commitment to patient safety and product integrity. With a focus on sustainability, Wockhardt endeavors to minimize its environmental impact while maximizing its positive contribution to society. Through strategic partnerships, collaborations, and a steadfast commitment to scientific excellence, Wockhardt continues to evolve as a dynamic and forward-thinking pharmaceutical organization, poised to shape the future of healthcare and deliver impactful solutions that improve lives around the world.
Company Details
Key Leadership
WOCKPHARMA Share Price: Frequently Asked Questions
What is the current share price of Wockhardt Limited?
Wockhardt Limited (WOCKPHARMA) trades at ₹2021.50 on NSE and BSE. Market cap ₹32.75K (Cr). Educational data only.
What is the P/E ratio of Wockhardt Limited?
Wockhardt Limited has a P/E of 80.22x vs industry average 34.89x.
What is the Bull Run score for Wockhardt Limited?
Wockhardt Limited has a Bull Run score of 24.6/100 based on 25+ financial parameters.
Does Wockhardt Limited pay dividends?
Wockhardt Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Wockhardt Limited?
Wockhardt Limited has ROE of 4.58%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Wockhardt Limited?
Wockhardt Limited has debt-to-equity of 0.43.
Is Wockhardt Limited a good investment?
Bull Run gives Wockhardt Limited a score of 24.6/100. This is not investment advice — consult a SEBI-registered advisor.